Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury.
Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury.
A proportion of patients infected with severe acute respiratory syndrome coronavirus 2 experience a range of neuropsychiatric symptoms months after infection, including cognitive deficits, depression and anxiety. The mechanisms underpinning such symptoms remain elusive. Recent research has demonstrated that nervous system injury can occur during COVID-19. Whether ongoing neural injury in the months after COVID-19 accounts for the ongoing or emergent neuropsychiatric symptoms is unclear. Within a large prospective cohort study of adult survivors who were hospitalized for severe acute respiratory syndrome coronavirus 2 infection, we analysed plasma markers of nervous system injury and astrocytic activation, measured 6 months post-infection: neurofilament light, glial fibrillary acidic protein and total tau protein. We assessed whether these markers were associated with the severity of the acute COVID-19 illness and with post-acute neuropsychiatric symptoms (as measured by the Patient Health Questionnaire for depression, the General Anxiety Disorder assessment for anxiety, the Montreal Cognitive Assessment for objective cognitive deficit and the cognitive items of the Patient Symptom Questionnaire for subjective cognitive deficit) at 6 months and 1 year post-hospital discharge from COVID-19. No robust associations were found between markers of nervous system injury and severity of acute COVID-19 (except for an association of small effect size between duration of admission and neurofilament light) nor with post-acute neuropsychiatric symptoms. These results suggest that ongoing neuropsychiatric symptoms are not due to ongoing neural injury.
Taquet, M
4553482e-a695-4b26-9ec1-3aa2499b7e5b
Skorniewska, Z
b5d8464d-17b4-43b6-a6c5-71057b89203a
Zetterberg, Henrik
65e1750c-2467-4f02-ac28-e0e41c3a76b2
JR, Geddes
cc9d2e57-d494-4271-ba03-a6b315e40309
CJ, Mummery
9b6e9106-02fa-47bc-8c10-78196f14d427
JD, Chalmers
d9b00ce8-be17-4269-abee-544380039b30
LP, Ho
79bf26b4-61e7-4ac6-a261-4a3a3daef396
Horsley, A
44595e4e-e60c-4b1d-ab8c-363cc02770e7
Marks, Michael
91d7c45a-1af5-408a-b966-4c29dae6e8af
Poinasamy, K
a28b1b07-547d-4c11-9c02-d7fe05f75133
Raman, Betty
7cbeb9a8-17fe-4a2d-8416-738945b667b9
OC, Leavy
64675740-9fb0-42bf-8344-48551fbe31ef
Elneima, O
f63465fa-6af2-4346-809d-248160659e7b
HJC, McAuley
d30efd13-9609-483f-8231-0bd44ab1a919
Shikotra, A
81f10100-8d6c-48a9-8c15-684a62fb9875
Singapuri, A
d9066904-5d50-4565-919b-d82d8e88a5cc
Sereno, M
4c47c567-36b6-4003-8e34-ea8e0f811298
RM, Saunders
4b7cf6ea-3614-4068-84d6-0879c290c158
VC, Harris
2f947df8-5ca6-42e0-8aeb-35ca8defeddd
Houchen-Wolloff, L
bf70a477-0d66-4e8d-a02e-53174a4350dc
Mansoori, P
38e99c08-4a1f-4b7c-bd47-0733ef01357f
NJ, Greening
44ef748a-20f5-4ccf-8840-1e2f3e18b7c4
EM, Harrison
072e9367-09a5-460f-ba4b-becd3942de2f
AB, Docherty
a335a2f4-9445-4541-b6bf-be9bfed7cb17
NI, Lone
aa5c6552-0d7b-4629-be36-6ef66f1e601f
Greenhalf, W
8a259791-6f89-4ebf-84bf-a81ea681e347
Quint, J
494897df-5a5c-4181-9e07-031a39181e53
Jones, Mark G.
a6fd492e-058e-4e84-a486-34c6035429c1
LV, Wain
ec3bb230-e14a-464e-b3a1-545c3f6bb031
CE, Brightling
7eea7ab6-1fe6-407a-b793-3cff71d90ca5
RE, Evans
f0f1df30-4c61-4219-9c5d-0e694a2710c5
Harrison, Paul
691ee6c1-6616-4995-8a71-841889e1812d
Koychev, Ivan
302fdeb4-8c17-4209-9c8f-c18bb93b0949
Group, PHOSP-COVID Study Collaborative
8a098ef7-703d-435b-bf37-cfc539409a30
27 December 2023
Taquet, M
4553482e-a695-4b26-9ec1-3aa2499b7e5b
Skorniewska, Z
b5d8464d-17b4-43b6-a6c5-71057b89203a
Zetterberg, Henrik
65e1750c-2467-4f02-ac28-e0e41c3a76b2
JR, Geddes
cc9d2e57-d494-4271-ba03-a6b315e40309
CJ, Mummery
9b6e9106-02fa-47bc-8c10-78196f14d427
JD, Chalmers
d9b00ce8-be17-4269-abee-544380039b30
LP, Ho
79bf26b4-61e7-4ac6-a261-4a3a3daef396
Horsley, A
44595e4e-e60c-4b1d-ab8c-363cc02770e7
Marks, Michael
91d7c45a-1af5-408a-b966-4c29dae6e8af
Poinasamy, K
a28b1b07-547d-4c11-9c02-d7fe05f75133
Raman, Betty
7cbeb9a8-17fe-4a2d-8416-738945b667b9
OC, Leavy
64675740-9fb0-42bf-8344-48551fbe31ef
Elneima, O
f63465fa-6af2-4346-809d-248160659e7b
HJC, McAuley
d30efd13-9609-483f-8231-0bd44ab1a919
Shikotra, A
81f10100-8d6c-48a9-8c15-684a62fb9875
Singapuri, A
d9066904-5d50-4565-919b-d82d8e88a5cc
Sereno, M
4c47c567-36b6-4003-8e34-ea8e0f811298
RM, Saunders
4b7cf6ea-3614-4068-84d6-0879c290c158
VC, Harris
2f947df8-5ca6-42e0-8aeb-35ca8defeddd
Houchen-Wolloff, L
bf70a477-0d66-4e8d-a02e-53174a4350dc
Mansoori, P
38e99c08-4a1f-4b7c-bd47-0733ef01357f
NJ, Greening
44ef748a-20f5-4ccf-8840-1e2f3e18b7c4
EM, Harrison
072e9367-09a5-460f-ba4b-becd3942de2f
AB, Docherty
a335a2f4-9445-4541-b6bf-be9bfed7cb17
NI, Lone
aa5c6552-0d7b-4629-be36-6ef66f1e601f
Greenhalf, W
8a259791-6f89-4ebf-84bf-a81ea681e347
Quint, J
494897df-5a5c-4181-9e07-031a39181e53
Jones, Mark G.
a6fd492e-058e-4e84-a486-34c6035429c1
LV, Wain
ec3bb230-e14a-464e-b3a1-545c3f6bb031
CE, Brightling
7eea7ab6-1fe6-407a-b793-3cff71d90ca5
RE, Evans
f0f1df30-4c61-4219-9c5d-0e694a2710c5
Harrison, Paul
691ee6c1-6616-4995-8a71-841889e1812d
Koychev, Ivan
302fdeb4-8c17-4209-9c8f-c18bb93b0949
Group, PHOSP-COVID Study Collaborative
8a098ef7-703d-435b-bf37-cfc539409a30